Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Ettenberg

Showing results (91-100 of 93) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 93 results.
Proceedings of the National Academy of Sciences of the United States of America|August 18, 2010
Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodiesSeth A Ettenberg, Olga Charlat, Michael P Daley, et al.
Oncogene|May 10, 2016
Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodiesP Bernasconi-Elias, T Hu, D Jenkins, et al.
Cancer Discovery|May 21, 2017
Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal CancersCarl U Bialucha, Scott D Collins, Xiao Li, et al.
Pageof 10

Showing results (91-100 of 93) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 93 results.
Proceedings of the National Academy of Sciences of the United States of America|August 18, 2010
Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodiesSeth A Ettenberg, Olga Charlat, Michael P Daley, et al.
Oncogene|May 10, 2016
Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodiesP Bernasconi-Elias, T Hu, D Jenkins, et al.
Cancer Discovery|May 21, 2017
Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal CancersCarl U Bialucha, Scott D Collins, Xiao Li, et al.
Pageof 10